Top Page
Anatara Lifesciences Ltd
(Sydney:ANR)
Anatara Lifesciences Ltd (ANR) vs. iShares MSCI Australia ETF (EWA)
Anatara Lifesciences Ltd Business Overview & Revenue Model
Anatara Lifesciences Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 746.36K | 969.46K | 644.03K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -511.80K | -633.97K | -748.91K | -24.76K | -24.68K | -6.26K |
| EBITDA | -1.56M | -1.96M | -1.46M | -3.21M | -2.97M | -3.01M |
| Net Income | -1.56M | -1.95M | -1.45M | -2.02M | -2.53M | -2.00M |
Balance Sheet | ||||||
| Total Assets | 1.15M | 1.15M | 1.67M | 1.42M | 1.77M | 4.33M |
| Cash, Cash Equivalents and Short-Term Investments | 101.36K | 101.36K | 982.11K | 401.18K | 1.17M | 3.43M |
| Total Debt | 407.42K | 407.42K | 0.00 | 0.00 | 65.80K | 79.92K |
| Total Liabilities | 612.42K | 612.42K | 306.85K | 494.83K | 403.35K | 496.67K |
| Stockholders Equity | 535.97K | 535.97K | 1.36M | 924.54K | 1.36M | 3.83M |
Cash Flow | ||||||
| Free Cash Flow | -1.59M | -2.27M | -1.25M | -2.26M | -2.24M | -2.10M |
| Operating Cash Flow | -1.59M | -2.27M | -1.25M | -2.26M | -2.23M | -2.10M |
| Investing Cash Flow | 0.00 | 0.00 | 50.00K | -1.73K | -56.56K | -3.98K |
| Financing Cash Flow | 1.39M | 1.39M | 1.83M | 1.49M | -22.44K | 2.85M |
Anatara Lifesciences Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | AU$33.06M | -9.09 | -143.71% | ― | 306.88% | ― | |
40 Underperform | AU$4.08M | -1.35 | -205.70% | ― | ― | 1.03% | |
40 Underperform | AU$10.57M | -1.79 | -166.70% | ― | ― | ― | |
40 Underperform | AU$2.17M | -4.33 | -28.49% | ― | ― | 46.43% | |
38 Underperform | AU$51.82M | -8.00 | -159.86% | ― | 110.44% | 35.90% | |
37 Underperform | AU$13.77M | -1.61 | -628.72% | ― | ― | 31.87% |
Anatara Lifesciences Ltd Corporate Events
Anatara Lifesciences Ltd has reported promising pre-clinical results for its Anti-Obesity Project, with the candidate compound AOC showing significant potential in managing weight reduction and controlling weight gain after cessation of weight loss treatments. Although the Mechanism of Action studies have faced delays due to international supply issues, the company remains committed to advancing its research and exploring further commercial opportunities. The project aims to develop an oral complementary medication to assist in weight management, and Anatara is actively pursuing business development discussions to capitalize on these findings.
Anatara Lifesciences Limited has announced a change in the director’s interest notice concerning Dr. David Brookes. The company disclosed that Dr. Brookes has disposed of 932,143 unlisted options, with no new securities acquired. This change reflects adjustments in Dr. Brookes’ holdings, which include both direct and indirect interests through various trusts and superfunds. The announcement is part of the company’s compliance with ASX listing rules, ensuring transparency in the director’s financial interests.
Anatara Lifesciences Ltd announced the cessation of 27,749,784 securities due to the expiry of options or other convertible securities without exercise or conversion. This development may impact the company’s capital structure and could influence investor perception regarding the company’s financial strategies.
Anatara Lifesciences Ltd announced a change in the director’s interest, with Dr. David Brookes acquiring additional shares through entities Tarandi and Dahlbrook Family Trust. This acquisition, valued at $40,000, reflects a strategic move that could influence the company’s market positioning and stakeholder confidence.
Anatara Lifesciences Ltd announced the issuance of 4,000,000 unquoted equity securities in the form of options expiring on November 26, 2028, with an exercise price of $0.025. This move is part of previously announced transactions and reflects the company’s ongoing efforts to strengthen its financial position and support its strategic initiatives, potentially impacting its market presence and stakeholder interests.
Anatara Lifesciences Ltd has completed the final allocation of shares under Tranche 2 of its two-tranche placement, issuing 66,352,417 ordinary shares. Additionally, 4,000,000 unlisted options were allotted to the Lead Manager, exercisable at $0.025 each and expiring in three years. This strategic move is expected to bolster Anatara’s financial position, supporting its ongoing product development and market expansion efforts.
Anatara Lifesciences Ltd has announced the cessation of 300,000 securities under the ASX code ANRAQ due to the expiry of options without exercise or conversion. This development may affect the company’s capital structure and could have implications for stakeholders regarding the company’s financial strategies and market positioning.
Anatara Lifesciences Ltd has issued a disclaimer regarding the information provided in their recent presentation, emphasizing that it should not be considered personal investment advice. The company stresses the importance of consulting a professional investment adviser before making any investment decisions based on the presentation. The release highlights that the information is based on sources deemed reliable, but no guarantees are made regarding its accuracy or completeness, and the company disclaims liability for any potential losses incurred by relying on the presentation.
Anatara Lifesciences faced challenges in 2025, notably with the GaRP-IBS Phase II trial not meeting its primary efficacy endpoint, although it showed significant symptom improvement. The company is optimistic about the potential commercial viability of GaRP, with forthcoming publications expected to aid in commercial considerations. Additionally, the Anti-Obesity project is progressing, with proof-of-concept studies nearing completion and preliminary findings being encouraging. Anatara continues to explore new opportunities, emphasizing products that address unmet needs, and remains committed to enhancing shareholder value.
Anatara Lifesciences Ltd has announced its Annual General Meeting, scheduled for November 20, 2025, to be held both virtually and in person in Adelaide, South Australia. This meeting provides a platform for shareholders to engage with the company, vote on key issues, and ask questions, reflecting the company’s commitment to transparency and stakeholder engagement.
Anatara Lifesciences Ltd has released its corporate governance statement for the financial year ending June 30, 2025, which is available on their website. The statement confirms the company’s adherence to the ASX Corporate Governance Council’s recommendations, ensuring transparency and accountability in its management and oversight practices. This move is likely to bolster stakeholder confidence and reinforce Anatara’s commitment to high governance standards.
Anatara Lifesciences Ltd has released its annual report for 2024-2025, emphasizing its commitment to providing evidence-based health solutions. The company’s strategy involves leveraging proprietary technology and forming strategic partnerships to develop a pipeline of health products, which is expected to enhance its market position and offer substantial value to stakeholders.